Optimizing Unrelated Donor Cord Blood Transplantation

Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Hematopoietic cell transplantation (HCT) can be curative for selected malignant and nonmalignant diseases.1-13 However, utilization and success of HCT are limited by several obstacles, primarily related to the importance of donor-recipient genetic match for favorable outcomes. While in most settings, best results are offered by human leukocyte antigen (HLA)14,15–identical sibling transplantatio...

Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia.

GT, a rare disorder of platelet function, can lead to life-threatening bleeding, particularly following the development of antiplatelet antibodies. Curative therapy includes HCT but previous reports are limited predominantly to matched siblings and have excluded CBT. Delayed or non-engraftment of platelets because of antiplatelet antibodies might be particularly concerning after CBT for GT. Her...

UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: MARROW OR UMBILICAL CORD BLOOD? Short title: Donor selection: Bone Marrow or Cord Blood?

Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors.

Acute graft-versus-host disease (GVHD) occurs less frequently after umbilical cord blood transplantation (UCBT). More recent investigations include the use of 2 partially human leukocyte antigen (HLA)-matched UCB units, or double UCB graft, to meet the minimum cell-dose requirement. The purpose of this analysis was to assess the relative risk of acute GVHD in 265 consecutive patients receiving ...

Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.

The potential role of unrelated donor cord blood transplantation (UD-CBT) in adults remains unclear. This study reports the results of UD-CBT in 22 adults with hematologic malignancies following conditioning with thiotepa, busulfan, cyclophosphamide, and antithymocyte globulin in 21, with thiotepa, fludarabine, and antithymocyte globulin in 1, and graft-versus-host disease (GVHD) prophylaxis wi...